Cover Image
市場調查報告書

液態切片的全球市場的預測 ∼2022年:循環腫瘤細胞、ctDNA、無細胞DNA

Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User - Global Forecast to 2022

出版商 MarketsandMarkets 商品編碼 364533
出版日期 內容資訊 英文 206 Pages
訂單完成後即時交付
價格
Back to Top
液態切片的全球市場的預測 ∼2022年:循環腫瘤細胞、ctDNA、無細胞DNA Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User - Global Forecast to 2022
出版日期: 2017年09月25日 內容資訊: 英文 206 Pages
簡介

液態切片的市場預計從2017年到2022年以23.4%的年複合成長率發展,2022年成長到20億4790萬美元的規模。癌症的盛行率的擴大,對非侵入性治療的愛好的擴大,R&D資金的可用性的擴大等的要素促進該市場的成長。

本報告提供全球液態切片的市場調查,市場及技術概要,市場成長的影響因素及市場機會分析,各產品&服務區分、循環生物標記、癌症類型、臨床用途、終端用戶、地區/主要國家趨勢與市場規模的變化與預測,競爭環境,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 市場概要
  • 市場成果:各臨床用途
  • 各地區的成長機會
  • 地區結構
  • 現有市場 vs 新興市場

第5章 市場概要

  • 簡介
  • 市場動態
    • 推動因素
    • 阻礙因素
    • 機會
    • 課題

第6章 市場分析:各產品與服務

  • 簡介
  • 化驗套件
  • 設備
  • 服務

第7章 市場分析:各循環生物標記

  • 簡介
  • 循環腫瘤細胞
  • 循環腫瘤來源DNA (ctDNA)
  • 無細胞DNA
  • 細胞外小胞 (EV)
  • 其他

第8章 市場分析:各臨床用途

  • 簡介
  • 癌症的早期篩檢
  • 治療的選擇決策
  • 治療監測
  • 復發監測

第9章 市場分析:各用途

  • 簡介
  • 癌症
    • 肺癌
    • 乳癌
    • 大腸癌
    • 前列腺癌
    • 肝癌
    • 其他
  • 其他

第10章 市場分析:各終端用戶

  • 簡介
  • 參考實驗室
  • 醫院、醫生的實驗室
  • 學術、研究中心
  • 其他

第11章 地區分析

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 其他
  • 其他地區

第12章 競爭環境

  • 市場排行榜

第13章 企業簡介

  • BIOCEPT, INC.
  • QIAGEN N.V.
  • ROCHE DIAGNOSTICS
  • BIO-RAD LABORATORIES, INC.
  • MYRIAD GENETICS, INC
  • MENARINI-SILICON BIOSYSTEMS
  • TROVAGENE, INC.
  • GUARDANT HEALTH, INC.
  • MDXHEALTH SA
  • GENOMIC HEALTH, INC.
  • RAINDANCE TECHNOLOGIES, INC
  • THERMO FISHER SCIENTIFIC INC.
  • ILLUMINA, INC.

第14章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MD 4456

"Global liquid biopsy market projected to grow at a CAGR of 23.4%"

The global liquid biopsy market is estimated to grow at a CAGR of 23.4% from 2017 to 2022, to reach USD 2,047.9 million by 2022. Increasing prevalence of cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market. Unclear Regulatory and reimbursement scenario is one of the major challenges faced by the market.

"Extracellular vesicles to register the highest CAGR during the forecast period"

Based on circulating biomarkers the market is categorized into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs) and other circulating biomarkers. The extracellular vesicles segment is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in EV research from biofluids such as the blood and urine of cancer patients as a means of disease diagnosis and therapeutic monitoring.

"The non-cancer application segment is projected to grow at the highest CAGR during the forecast period"

Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications (which include reproductive health and organ transplant diagnostics). The non-cancer application segment is expected to be the fastest-growing segment in the market during the forecast period. This is due to the growing application in noninvasive prenatal testing (NIPT), using cell-free DNA assays in the identification of trisomies (which includes 13, 16, and 18), gender identification, and other genetic abnormalities such as monosomy X and microdeletions. NIPT is also rapidly replacing amniocentesis in high-risk pregnancies, thus expanding its application.

"Asia Pacific to witness the highest growth during the forecast period (2017-2022)"

North America is expected to account for the largest share of the global liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of cancer, and improving healthcare infrastructure are driving the growth of the liquid biopsy market.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1- 15%, Tier 2- 45%, and Tier 3-40%
  • By Designation - C-level- 27%, Director Level-33%, Others-40%
  • By Region - North America-25%, Europe-45%, Asia-Pacific-15%, RoW-15%

Some of the major market players in the liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDxHealth SA (US).

Research Coverage:

The report analyzes the liquid biopsy market and aims at estimating market size and future growth potential of this market based on various segments such as by product, circulating biomarker, clinical application, application, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global liquid biopsy market. The report analyzes the global liquid biopsy market by product, medical specialty, application, end user, and region
  • Innovation: Detailed insights on upcoming trends and product launches in the global liquid biopsy market
  • Market Development: Comprehensive information on the lucrative emerging markets by product, medical specialty, application, end user, and region
  • Market Diversification: Exhaustive information about growing geographies, recent developments, and investments in the global liquid biopsy market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and capabilities of liquid biopsy devices of leading players in the global market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH APPROACH
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Primary sources
      • 2.1.2.2. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. LIQUID BIOPSY: MARKET OVERVIEW
  • 4.2. LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION (2017)
  • 4.3. LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4. LIQUID BIOPSY MARKET: GEOGRAPHIC MIX
  • 4.5. LIQUID BIOPSY MARKET: ESTABLISHED VS. EMERGING MARKETS

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing prevalence of cancer
      • 5.2.1.2. Increasing preference for noninvasive procedures
      • 5.2.1.3. Initiatives undertaken by government and global health organizations
      • 5.2.1.4. Technological advancement to augment market revenues
      • 5.2.1.5. Rising emphasis on personalized medicine
      • 5.2.1.6. Availability of funding for liquid biopsy R&D
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Low sensitivity and specificity
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Growing interest in liquid biopsy
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Unclear regulatory and reimbursement scenario

6. LIQUID BIOPSY MARKET, BY PRODUCT AND SERVICE

  • 6.1. INTRODUCTION
  • 6.2. ASSAY KITS
  • 6.3. INSTRUMENTS
  • 6.4. SERVICES

7. LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

  • 7.1. INTRODUCTION
  • 7.2. CIRCULATING TUMOR CELLS
  • 7.3. CIRCULATING TUMOR DNA (CTDNA)
  • 7.4. CELL-FREE DNA
  • 7.5. EXTRACELLULAR VESICLES (EVS)
  • 7.6. OTHER CIRCULATING BIOMARKERS

8. LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. EARLY CANCER SCREENING
  • 8.3. THERAPY SELECTION
  • 8.4. TREATMENT MONITORING
  • 8.5. RECURRENCE MONITORING

9. LIQUID BIOPSY MARKET, BY APPLICATION

  • 9.1. INTRODUCTION
  • 9.2. CANCER APPLICATIONS
    • 9.2.1. LUNG CANCER
    • 9.2.2. BREAST CANCER
    • 9.2.3. COLORECTAL CANCER
    • 9.2.4. PROSTATE CANCER
    • 9.2.5. LIVER CANCER
    • 9.2.6. OTHER CANCERS
  • 9.3. NON-CANCER APPLICATIONS

10. LIQUID BIOPSY MARKET, BY END USER

  • 10.1. INTRODUCTION
  • 10.2. REFERENCE LABORATORIES
  • 10.3. HOSPITALS AND PHYSICIAN LABORATORIES
  • 10.4. ACADEMIC AND RESEARCH CENTERS
  • 10.5. OTHER END USERS

11. LIQUID BIOPSY MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. US
    • 11.2.2. CANADA
  • 11.3. EUROPE
    • 11.3.1. GERMANY
    • 11.3.2. FRANCE
    • 11.3.3. UK
    • 11.3.4. REST OF EUROPE
  • 11.4. ASIA PACIFIC
    • 11.4.1. JAPAN
    • 11.4.2. CHINA
    • 11.4.3. INDIA
    • 11.4.4. REST OF ASIA PACIFIC
  • 11.5. REST OF THE WORLD (ROW)

12. COMPETITIVE LANDSCAPE

  • 12.1. MARKET RANKING ANALYSIS

13. COMPANY PROFILES (OVERVIEW, PRODUCTS OFFERED, STRENGTH OF PRODUCT PORTFOLIO, BUSINESS STRATEGY EXCELLENCE, RECENT DEVELOPMENTS.)*

  • 13.1. BIOCEPT, INC.
  • 13.2. QIAGEN N.V.
  • 13.3. ROCHE DIAGNOSTICS
  • 13.4. BIO-RAD LABORATORIES, INC.
  • 13.5. MYRIAD GENETICS, INC
  • 13.6. MENARINI-SILICON BIOSYSTEMS
  • 13.7. TROVAGENE, INC.
  • 13.8. GUARDANT HEALTH, INC.
  • 13.9. MDXHEALTH SA
  • 13.10. GENOMIC HEALTH, INC.
  • 13.11. RAINDANCE TECHNOLOGIES, INC
  • 13.12. THERMO FISHER SCIENTIFIC INC.
  • 13.13. ILLUMINA, INC.

*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Key relationships might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. INSIGHTS OF INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 14.5. AVAILABLE CUSTOMIZATIONS
  • 14.6. RELATED REPORTS
  • 14.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: CONFERENCES AND AWARENESS PROGRAMS ON LIQUID BIOPSY
  • TABLE 2: LIQUID BIOPSY PRODUCTS LAUNCHED IN RECENT YEARS
  • TABLE 3: LIQUID BIOPSY MARKET: FUNDING (2014 - 2017)
  • TABLE 4: COMPANIES SELLING/DEVELOPING LIQUID BIOPSY TESTS FOR ONCOLOGY, IN THE US
  • TABLE 5: LIQUID BIOPSY MARKET, BY PRODUCT AND SERVICE, 2015-2022 (USD MILLION)
  • TABLE 6: LIQUID BIOPSY MARKET FOR ASSAY KITS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 7: SPECIFICATIONS: NGS AND DDPCR FOR CANCER LIQUID BIOPSIES
  • TABLE 8: LIQUID BIOPSY MARKET FOR INSTRUMENTS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 9: LIQUID BIOPSY MARKET FOR SERVICES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 10: ADVANTAGES AND LIMITATIONS OF CTCS, CTDNA, AND EXOSOMES
  • TABLE 11: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2015-2022 (USD MILLION)
  • TABLE 12: COMPANIES ACTIVE IN THE CTCS SEGMENT
  • TABLE 13: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 14: LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 15: LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 16: LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 17: LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 18: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 19: LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY/REGION, 2015-2022 (USD THOUSANDS)
  • TABLE 20: LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 21: LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 22: LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 23: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 24: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 25: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 26: LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 27: LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 28: LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 29: LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 30: LIQUID BIOPSY MARKET FOR LIVER CANCER, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 31: LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 32: LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 33: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 34: LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 35: LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY COUNTRY/ REGION, 2015-2022 (USD MILLION)
  • TABLE 36: LIQUID BIOPSY MARKET FOR ACADEMIC AND RESEARCH CENTERS, BY COUNTRY/ REGION, 2015-2022 (USD MILLION)
  • TABLE 37: LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 38: LIQUID BIOPSY MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 39: ESTIMATED NEW CASES OF CANCER IN 2017, US
  • TABLE 40: NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 41: NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 42: NORTH AMERICA: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 43: NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 44: NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 45: NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 46: NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 47: US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 48: US: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 49: US: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 50: US: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 51: US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 52: US: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 53: OVERVIEW OF THE BREAST, CERVICAL, AND COLORECTAL CANCER SCREENING PROGRAMS ACROSS CANADA
  • TABLE 54: CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 55: CANADA: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 56: CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 57: CANADA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 58: CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 59: CANADA: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 60: EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 61: EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 62: EUROPE: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 63: EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 64: EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 65: EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 66: EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 67: GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 68: GERMANY: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 69: GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 70: GERMANY: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 71: GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 72: GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 73: FRANCE: KEY MARKET INDICATORS
  • TABLE 74: FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 75: FRANCE: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 76: FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 77: FRANCE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 78: FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 79: FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 80: UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 81: UK: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 82: UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 83: UK: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 84: UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 85: UK: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 86: ROE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 87: ROE: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 88: ROE: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 89: ROE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 90: ROE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 91: ROE: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 92: ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 93: ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 94: ASIA PACIFIC: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 95: ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 96: ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TYPE OF CANCER, 2015-2022 (USD MILLION)
  • TABLE 97: ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 98: ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 99: JAPAN: KEY MARKET INDICATORS
  • TABLE 100: JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 101: JAPAN: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 102: JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 103: JAPAN: LIQUID BIOPSY MARKET, BY TYPE OF CANCER, 2015-2022 (USD MILLION)
  • TABLE 104: JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 105: JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 106: CHINA: KEY MARKET INDICATORS
  • TABLE 107: CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 108: CHINA: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 109: CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 110: CHINA: LIQUID BIOPSY MARKET, BY TYPE OF CANCER, 2015-2022 (USD MILLION)
  • TABLE 111: CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 112: CHINA: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 113: INDIA: KEY MARKET INDICATORS:
  • TABLE 114: INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 115: INDIA: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 116: INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 117: INDIA: LIQUID BIOPSY MARKET, BY TYPE OF CANCER, 2015-2022 (USD MILLION)
  • TABLE 118: INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 119: INDIA: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 120: ROAPAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 121: ROAPAC: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 122: ROAPAC: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 123: ROAPAC: LIQUID BIOPSY MARKET, BY TYPE OF CANCER, 2015-2022 (USD MILLION)
  • TABLE 124: ROAPAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 125: ROAPAC: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 126: ROW: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015-2022 (USD MILLION)
  • TABLE 127: ROW: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 128: ROW: LIQUID BIOPSY MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 129: ROW: LIQUID BIOPSY MARKET, BY TYPE OF CANCER, 2015-2022 (USD MILLION)
  • TABLE 130: ROW: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 131: ROW: LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 132: LIQUID BIOPSY MARKET, BY KEY PLAYER, 2016
  • TABLE 133: CHF TO USD CONVERSION RATES (2014-2016)

LIST OF FIGURES

  • FIGURE 1: LIQUID BIOPSY: MARKET SEGMENTATION
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 5: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6: LIQUID BIOPSY MARKET, BY PRODUCT AND SERVICE, 2017 VS. 2022
  • FIGURE 7: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2017 VS. 2022
  • FIGURE 8: LIQUID BIOPSY MARKET, BY APPLICATION, 2017 VS. 2022
  • FIGURE 9: LIQUID BIOPSY MARKET, BY END USER, 2017 VS. 2022
  • FIGURE 10: GEOGRAPHICAL SNAPSHOT OF THE GLOBAL LIQUID BIOPSY MARKET
  • FIGURE 11: INCREASING CANCER PREVALENCE-MAJOR GROWTH DRIVER FOR THE LIQUID BIOPSY MARKET
  • FIGURE 12: THERAPY SELECTION SEGMENT TO DOMINATE THE LIQUID BIOPSY MARKET IN 2017
  • FIGURE 13: NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF THE LIQUID BIOPSY MARKET IN 2017
  • FIGURE 14: ASIA PACIFIC TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 15: EMERGING MARKETS TO GROW AT HIGHER CAGRS FROM 2017 TO 2022
  • FIGURE 16: LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: ESTIMATED NEW CANCER CASES AND ESTIMATED DEATHS IN US (2017)
  • FIGURE 18: CANCER PREVALENCE AND MORTALITY RATE, BY COUNTRY (2012)
  • FIGURE 19: PUBMED PUBLICATIONS-LIQUID BIOPSY
  • FIGURE 20: ESTIMATED NEW CANCER CASES AND DEATHS (2016)
  • FIGURE 21: NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
  • FIGURE 22: US: CANCER STATISTICS
  • FIGURE 23: CANADA: CANCER STATISTICS
  • FIGURE 24: EUROPE: PROPORTION OF DEATHS DUE TO CANCER IN THE EU (2013)
  • FIGURE 25: EUROPE: DEATHS DUE TO CANCER IN THE POPULATION AGED 65 AND OVER (2013)
  • FIGURE 26: GERMANY: CANCER INCIDENCE AND PREVALENCE, 2010 VS. 2015
  • FIGURE 27: UK: ESTIMATED NUMBER OF PEOPLE LIVING WITH CANCER
  • FIGURE 28: ROE: INCIDENCE AND PREVALENCE OF CANCER, 2015
  • FIGURE 29: ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT
  • FIGURE 30: JAPAN: CANCER INCIDENCE AND PREVALENCE NUMBER, 2010 VS. 2015
  • FIGURE 31: CHINA: CANCER INCIDENCE AND PREVALENCE NUMBER, 2010 VS 2015
  • FIGURE 32: INDIA: CANCER INCIDENCE AND PREVALENCE NUMBER, 2010 VS 2015
  • FIGURE 33: REST OF ASIA PACIFIC: NUMBER OF CANCER CASES, 2015
  • FIGURE 34: BIOCEPT, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 35: QIAGEN N.V.: COMPANY SNAPSHOT (2016)
  • FIGURE 36: ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2016)
  • FIGURE 37: BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 38: MYRIAD GENETICS, INC: COMPANY SNAPSHOT (2016)
  • FIGURE 39: MENARINI GROUP: COMPANY SNAPSHOT (2016)
  • FIGURE 40: TROVAGENE INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 41: MDXHEALTH: COMPANY SNAPSHOT (2016)
  • FIGURE 42: GENOMIC HEALTH, INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 43: THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2016)
  • FIGURE 44: ILLUMINA INC.: COMPANY SNAPSHOT (2016)
Back to Top